VanEck Pharmaceutical ETF $PPH Shares Sold by Fluent Financial LLC

Fluent Financial LLC reduced its position in VanEck Pharmaceutical ETF (NASDAQ:PPH) by 31.0% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 26,901 shares of the company’s stock after selling 12,091 shares during the period. VanEck Pharmaceutical ETF accounts for about 1.1% of Fluent Financial LLC’s portfolio, making the stock its 23rd largest position. Fluent Financial LLC owned approximately 0.29% of VanEck Pharmaceutical ETF worth $2,945,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of PPH. Avior Wealth Management LLC purchased a new position in VanEck Pharmaceutical ETF in the third quarter worth $1,685,000. Rye Brook Capital LLC lifted its holdings in shares of VanEck Pharmaceutical ETF by 4.3% during the 3rd quarter. Rye Brook Capital LLC now owns 70,255 shares of the company’s stock valued at $7,691,000 after purchasing an additional 2,925 shares during the last quarter. Integrated Wealth Concepts LLC purchased a new stake in shares of VanEck Pharmaceutical ETF during the 2nd quarter valued at $78,000. IFP Advisors Inc boosted its position in shares of VanEck Pharmaceutical ETF by 115.7% in the 2nd quarter. IFP Advisors Inc now owns 537 shares of the company’s stock worth $59,000 after purchasing an additional 288 shares in the last quarter. Finally, TD Waterhouse Canada Inc. boosted its position in shares of VanEck Pharmaceutical ETF by 130.0% in the 2nd quarter. TD Waterhouse Canada Inc. now owns 230 shares of the company’s stock worth $25,000 after purchasing an additional 130 shares in the last quarter.

VanEck Pharmaceutical ETF Stock Performance

PPH stock traded down $1.47 on Tuesday, hitting $109.23. 346,675 shares of the company’s stock were exchanged, compared to its average volume of 311,203. VanEck Pharmaceutical ETF has a 12-month low of $90.60 and a 12-month high of $118.00. The firm has a 50 day moving average price of $111.83 and a two-hundred day moving average price of $107.52. The stock has a market cap of $1.03 billion, a P/E ratio of 20.21 and a beta of 0.45.

VanEck Pharmaceutical ETF Cuts Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, October 6th. Shareholders of record on Thursday, October 1st were paid a $0.36 dividend. This represents a $1.44 dividend on an annualized basis and a yield of 1.3%. This is a drop from VanEck Pharmaceutical ETF’s previous quarterly dividend of $0.6248. The ex-dividend date was Thursday, October 1st.

VanEck Pharmaceutical ETF Company Profile

The VanEck Pharmaceutical ETF (PPH) is an exchange-traded fund that is based on the MVIS US Listed Pharmaceutical 25 index, a market-cap-weighted index of 25 of the largest global pharmaceutical firms. PPH was launched on Feb 1, 2000 and is managed by VanEck.